Mode
Text Size
Log in / Sign up
N/A N=36

chronOS Inject in Proximal Tibial Fractures

Closed Proximal Tibial Fracture Schatzker I - VI · Closed Proximal Tibial Fracture AO-OTA 41 · Closed Proximal Tibial Fracture AO-OTA 42

Enrolled (actual)
36
Serious AEs
2.8%
Results posted
Jun 2014
Primary outcome: Primary: Fracture Union — 27; 2 participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
chronOS Inject (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Synthes GmbH
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Fracture Union
27; 2
PRIMARY
Articular Subsidence
28; 1
PRIMARY
Mean Time to Union
7.5
SECONDARY
Absorption Rate of Calcium Phosphate Cement
0.64
SECONDARY
Patients Who Reached Full Weight Bearing
29
SECONDARY
Total Range of Motion
17; 11; 1; 0; 0
SECONDARY
Anatomical Gradings Assessed Radiographically
28; 28; 29
SECONDARY
Patient's Satisfaction
80.52
SECONDARY
Surgeon's Satisfaction With the Product
87.3; 87; 87; 81.7; 77.1; 68.6
SECONDARY
Extension Ability and Stability
26; 3; 28; 1
SECONDARY
Peri-operative Complications
0; 0; 0; 0
SECONDARY
SF-12 Short Form Health Survey Physical Composite Score (PCS)
37.02; 42.43 0.0166 sig
SECONDARY
SF-12 Short Form Health Survey Mental Composite Score (MCS)
46.3; 46.45 0.3785
SECONDARY
VAS Leg Pain Intensity
61.19; 17 <0.0001 sig
SECONDARY
VAS Leg Pain Frequency
57.28; 20.52 <0.0001 sig
SECONDARY
Lysholm Knee Scale
14; 11; 3; 1

Summary

The primary objective of this study is to observe the safety, the radiological and clinical outcomes of chronOS Inject after having been used as bone void filler in internal fixation of proximal tibial fractures.

Eligibility Criteria

Inclusion Criteria

  • Subjects with closed proximal tibial fractures defined by : Tibia plateau, Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
  • Skeletally mature adult 18 years or older, with close of growth plate at the time of surgery
  • Psychosocially, mentally and physically able to fully comply with this protocol including adhering to scheduled visits, treatment plan, completing forms, and other study procedures
  • Personally signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the study

Exclusion Criteria

  • Open fractures with severe soft tissue damage
  • Proximal tibial fractures with tumor or osteomyelitis
  • Any tibial anatomy or disease process that would interfere with deployment or performance of the device as defined by the surgeon
  • Osteopenia or Osteoporosis: if dual energy x-ray absorptiometry (DEXA) is required, exclusion will be defined as a DEXA bone density measured T score 40 kg/m2 or weight more than 50 kg over ideal body weight
  • Active malignancy. A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and there has been no clinical signs or symptoms of the malignancy >5 years
  • Known or documented history of communicable disease, including AIDS and HIV
  • Active Hepatitis (receiving medical treatment within two years)
  • Active systemic or local infection
  • Active rheumatoid arthritis, non-controlled diabetes mellitus, or any other medical condition(s) that would represent a significant increase in surgical risk or interfere with normal healing
  • Current or recent history (within last 2 years) of substance abuse (e.g., recreational drugs, narcotics, or alcohol)
  • Immunologically suppressed, or has received systemic steroids, excluding nasal steroids, at any dose daily for >1 month within last 12 months
  • Pregnant or planning to become pregnant during study period
  • Involved in study of another investigational product that may affect outcome
  • History of psychosocial disorders that could prevent accurate completion of self reporting assessment scales
  • Patients who are incarcerated
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02056834). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search